Cu 64 PSMA I&T - Curium Pharma
Alternative Names: 64-Copper-PSMA-I&T - Curium; 64-Cu-PSMA-I&T; Copper-64 prostate specific membrane antigen I&T; Cu-64-PSMA-I&TLatest Information Update: 22 Oct 2025
At a glance
- Originator Curium Pharma
- Class Antineoplastics; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Prostate cancer
Most Recent Events
- 18 Sep 2025 Phase-II clinical trials in Prostate cancer (Diagnosis) in Japan (IV) (jRCT2031250225)
- 08 Jul 2025 PDRadiopharma files an IND application with the PMDA in Japan for Prostate cancer
- 08 Jul 2025 PDRadiopharma plans a clinical trial in Prostate cancer (Diagnosis, Newly diagnosed) in Japan(IV)